Top Markets
Coin of the day
Lysogene S.A. Lysogene S.A.

Lysogene S.A.

LYS
Rangering i aksjer #36618
Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy,... Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy, dedicated to discovering and advancing treatments for children affected by severe neurodegenerative lysosomal storage disorders. Its development pipeline includes LYS-SAF302, which is currently undergoing Phase II/III clinical trials for mucopolysaccharidosis type IIIA (MPS IIIA). Another promising candidate, LYS-GM101, is in Phase I/II development, targeting GM1 gangliosidosis. The company has also forged a research alliance with the Weizmann Institute of Science to pioneer novel adeno-associated virus (AAV) gene therapy approaches for conditions such as neuronopathic Gaucher disease, Parkinson's disease, and other related illnesses. Lysogene S.A. was established in 2009 and is headquartered in Neuilly-sur-Seine, France.
Aksjekurs
$0.30221445
Sist synkronisert: 2023-05-22
Markedsverdi
$2.49M
Endring (1 dag)
-0.10%
Endring (1 år)
0.00%
Land
FR
Handel Lysogene S.A. (LYS)

Kategori

P/B-forhold for Lysogene S.A. (LYS)
P/B-forhold per 2026 TTM: 0
Ifølge Lysogene S.A. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Lysogene S.A. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.3419 -
US
6.2413 -
NL
- -
CH
- -
KR
3.4612 -
BE